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Background and purpose: Mutations in the NOTCH3 gene cause cerebral auto-
somal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL), a cerebral small vessel disease manifesting with stroke, migraine
and dementia in adults. The disease displays significant phenotypic variability
that is incompletely explained. Early abnormalities in vascular function have
been shown in animal models. We postulated that studying changes in vascular
function may offer insights into disease progression.
Methods: Twenty-two subjects with CADASIL [50% female, 50 (11) years]
from 19 pedigrees were included in a longitudinal multimodality study using
brain magnetic resonance imaging (MRI), clinical measures, neuropsychology
and measures of peripheral vascular function. MRI studies included measure-
ment of structural brain changes, cerebral blood flow (CBF) and cerebrovascu-
lar reactivity by arterial spin labelling and a CO2 respiratory challenge.
Results: Over 2 years, new stroke or transient ischaemic attack (TIA)
occurred in five (23%) subjects and new significant disability in one (5%).
There were significant increases in number of lacunes, subcortical hyperinten-
sity volume and microbleeds, and a decrease in brain volume. CBF declined
by 3.2 (4.5) ml/100 g/min over 2 years. CBF and carotid–femoral pulse wave
velocity at baseline predicted change in subcortical hyperintensity volume at
follow-up. Carotid intima-media thickness and age predicted brain atrophy.
Baseline CBF was lower in subjects who showed a decline in attention and
working memory.
Conclusions: Cerebral blood flow predicts radiological progression of hyperin-
tensities and thus is a potential biomarker of disease progression in CADA-
SIL. Over 2 years, there were changes in several relevant imaging biomarkers
(CBF, brain volume, lacunes, microbleeds and hyperintensity volume). Future
studies in CADASIL should consider assessment of CBF as prognostic factor.
Introduction
Cerebral autosomal dominant arteriopathy with sub-
cortical infarcts and leukoencephalopathy (CADA-
SIL) is due to mutations in the NOTCH3 gene and is
the most common monogenic cause of stroke [1].
Population prevalence has been estimated to be at
least 1 in 10 000 [2], but the prevalence of potentially
disease-causing NOTCH3 mutations in public exomes
is much higher [3]. There are no effective therapeutic
interventions to slow disease progression [4].
The principal manifestations of CADASIL, includ-
ing stroke, migraine and cognitive dysfunction, are
well-described [4]. However, there is marked pheno-
typic variability, even in individuals with the same
mutation. This hampers individual prognostication
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and impedes clinical trials since clinical end-point vari-
ability and slow progression greatly inflate sample size
in any potential therapeutic trial [5].
There is a limited understanding of the factors that
underlie clinical progression. The clinical predictors
include age and dementia, but only current smoking
and hypertension may be modifiable [6,7]. Magnetic
resonance imaging (MRI) markers of cerebral small
vessel disease such as lacunes [8] and atrophy [9] have
been shown to predict clinical worsening to varying
degrees [10]. However, these may manifest fairly late
in the disease pathway.
Impaired clearance of the mutated NOTCH3 extra-
cellular domain appears to lead to toxic protein aggre-
gation, cellular damage and degeneration of small
cerebral vessels and pericytes [11,12]. This is associ-
ated with vascular dysfunction [13,14] that precedes
histological evidence of brain damage in mouse mod-
els [12] In a cross-sectional study in subjects with
CADASIL, we showed that impaired cerebral and
peripheral vasoreactivity were associated with higher
numbers of lacunes [15]. If changes in vascular func-
tion occur early, are pathophysiologically relevant and
are amenable to interventions, this may make them
excellent biomarkers [12].
Therefore, we aimed to investigate longitudinal
changes in vascular function in people with CADASIL.
We aimed to establish if they are relevant in clinical or
radiological progression of CADASIL, and whether
they have merit for inclusion in future studies.
Materials and methods
Study cohort
Subjects were prospectively recruited between May
2013 and November 2013 from a specialist neurovas-
cular genetics clinic at the Queen Elizabeth University
Hospital Glasgow, United Kingdom. Eligible subjects
were aged 18 years or over with a genetic diagnosis of
CADASIL. Exclusion criteria included contraindica-
tions to MRI, current use of calcium channel blockers
or angiotensin-converting enzyme inhibitors, and type
II respiratory failure. Subjects provided written
informed consent.
The study was approved by the West of Scotland
Research Ethics Service (12/WS/0295). The study was
conducted in accordance with standards laid down in
the Helsinki Declaration of 1975 (revised 1983). Sub-
jects underwent study procedures at recruitment, 1
and 2 years, as well as telephone calls at 6 monthly
intervals to ensure no clinical changes were missed.
Clinical and demographic data, including cardiovas-
cular risk factors, were collected during the study
period. A history of transient ischaemic attacks (TIA)
or stroke, psychiatric disorders, depression, migraine,
seizures or other medical conditions was obtained at
each review. Neurological impairment was assessed
using the National Institutes of Health Stroke Scale
[16]. Global disability was assessed by the modified
Rankin Scale (mRS), using the structured Rankin
Focused Assessment tool [17]. Moderate or severe dis-
ability was defined as mRS ≥ 3.
Study procedures
All peripheral vascular tests took place within a temper-
ature-controlled room (22–24°C) using a standardised
protocol. Vascular phenotyping included ultrasound
assessment of flow-mediated dilatation (FMD) of the
brachial artery and ultrasound measurement of carotid
intima-media thickness (CIMT). Carotid-femoral pulse
wave velocity (PWV) was measured using applanation
tonometry (SphygmoCor; AtCor Medical, Sydney,
Australia). Detailed description of methods and analy-
sis used in this study have been published previously
[15] and are included in Appendix S1.
Neuropsychological assessment was carried out over
one or two sessions at each time-point by a specialist
clinical neuropsychologist (B.C.), and included stan-
dardised tests of estimated premorbid ability, global
cognitive function, processing speed, verbal and visual
attention and working memory, verbal and visual epi-
sodic memory, visuospatial function, verbal fluency,
verbal reasoning and executive function. The domains
of speed, attention/working memory and executive
function were chosen a priori for analysis. Composite
domain scores were derived from individual tests by
converting raw scores to standardised scores (cor-
rected for age, or age and education, with reference to
published normative tables). The mean of scores
within a particular cognitive domain was then calcu-
lated; higher composite scores represented better per-
formance. Details of the components of each
composite score can be found in Appendix S1. Trail-
making B minus A time was also analysed separately
(measured in seconds, with higher values indicating
worse performance). For analysis, change in compos-
ite scores between year 2 and baseline were cate-
gorised into decline or improvement for comparison
with vascular markers.
Brain MRI acquisition
Subjects were scanned on a 3T MRI GE Signa Excite
HD scanner with an eight- channel head coil (GEMedi-
cal Systems, Milwaukee, WI, USA). MRI sequences
used for this study have been reported in detail
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
BRAIN IMAGING FACTORS IN CADASIL 221
previously [15] and are included in Appendix S1.
Briefly, the protocol included high-resolution millimet-
ric, three-dimensional (3D), T1-weighted, 5 mm T2-
weighted fluid-attenuated inversion recovery (FLAIR),
T2*-weighted susceptibility-weighted angiography
(SWAN) and 3D magnetic resonance angiography. 3D
pseudo-continuous arterial spin labelling MRI was per-
formed with the patient breathing 15 l/min air, and
repeated whilst breathing 40 l/min of 6% CO2/air. A
close-fitting gas mask (Ref 1141; Intersurgical, Woking-
ham, United Kingdom) and unidirectional breathing
circuit (Ref 2013014; Intersurgical) were used to admin-
ister the gases. Expiratory ports were closed, and gauze
swabs and tape were used to improve fit. Gas concen-
trations and patient observations were recorded
throughout (Veris Vital Signs Monitor; MEDRAD,
Indianola, IA, USA).
Image processing
Cerebral microbleeds, lacunes and subcortical hyperin-
tensities (SHs) were defined as per recent neuroimag-
ing standards [18]. Location and number of
microbleeds were recorded using the Microbleed
Anatomical Rating Scale at baseline [19] using SWAN
images and with reference to other sequences. Incident
microbleeds identified on serial scans were added to
the baseline total by one rater.
FMRIB software library (FSL) version 5.0 tools,
including SIENAX and SIENA, were used to deter-
mine intracranial cavity volume (ICCV) from SWAN
images and brain volume from T1-weighted images
[20–22]. Changes in global brain volume between
baseline and year 2 [percentage brain volume change,
(PBVC)] were calculated for all subjects using SIENA.
Hyperintense signal abnormalities on FLAIR in
white matter, grey matter and brainstem were termed
SHs [18]. SHs were analysed on FLAIR images. SH
volumes were initially estimated as described previ-
ously [23]. These initial estimates were then edited by
a trained rater. The optimal FLAIR threshold for
each patient was chosen by inspection of the baseline
map, and used for the following years. The total vol-
ume of SH was normalised for ICCV in each patient
[normalised SH volume = (SH volume/ICCV) × 100].
Baseline lacunes were counted and segmented man-
ually using two-dimensional and 3D thresholding
tools on 3D T1-weighted images (Analyze version
11.0; AnalyzeDirect, Stilwell, KS, USA).
Incident lacunes were identified using difference
imaging from T1-weighted images obtained at baseline
and follow-up. SWAN maps were registered to T1-
weighted, skull stripped and used to mask the T1-
weighted image (using FSL tools) [21]. The baseline
brain image was registered to Montreal Neurological
Institute 1-mm brain template with 6 degrees of free-
dom. Year 1 and 2 brain images were then registered
to this image with 12 degrees of freedom. The images
were bias corrected, and follow-up images were sub-
tracted from baseline image to create a difference map
at year 1 and year 2. The difference map was
reviewed, with reference to original images, to identify
new lacunes (Fig. 1).
At each time-point, structural scans, SH masks and
arterial spin labelling (ASL) scans were coregistered
(Analyze version 11). The transformed T1-weighted
image was segmented into parenchyma (brain), grey,
and white matter masks [24]. SH pixels were removed
from grey and white matter masks. Quantitative cere-
bral blood flow (CBF) maps were generated using an
Figure 1 Identification of new lacunes. T1-weighted images at each time-point were coregistered to the Montreal Neurological Institute
template and bias corrected. This allowed creation of difference maps to identify new areas of signal change. In each new area, refer-
ence was made to original T1-weighted images, and to other available sequences to confirm if it was a new lacune. The arrow high-
lights an area of signal change, which represented new white matter hyperintensity and a perivascular space. One new lacune can be
seen on each difference map as a black area.
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in-house macro for Image J (Rasband, W.S., ImageJ,
National Institutes of Health, Bethesda, MD, USA;
http://imagej.nih.gov/ij/, 1997–2014.) Masks were then
applied to CBF maps to measure CBF and cere-
brovascular reactivity (CVR) in brain regions. Change
in CBF (%ΔCBF) was corrected for change in end-
tidal CO2 (EtCO2) to calculate cerebrovascular reac-
tivity (CVRASL):





Expiratory gas data were used if EtCO2 whilst
breathing air was between 3.5 and 6.5%, suggesting
reasonable mask seal.
Statistical analysis
Statistical analysis was performed with IBM SPSS
version 24 (IBM, Armonk, NY, USA).
A composite clinical outcome (based on other
CADASIL studies [25]) at 2 years was used: a new
stroke or TIA or new moderate-to-severe disability
(mRS 3–5) in those without significant disability
(mRS 0–2) at baseline, or worsening of mRS of 1 or
more grades in those with significant disability (mRS
3–5) at baseline.
Data were both inspected for normality and
assessed with Shapiro-Wilks test. Box plots were
examined for outliers. Change in continuous variables
over time was analysed with a one-way repeated mea-
sures ANOVA. Where there was a significant change, a
post hoc contrast between baseline and year 2 was per-
formed. Related-samples Friedman two-way tests were
used for non-parametric data. When there was a sig-
nificant change, pairwise comparisons with a Bonfer-
roni correction for multiple comparisons was used.
PBVC between baseline and year 2 was assessed with
a one-way t test.
Associations of outcome variables with baseline
variables was determined using Spearman rank corre-
lations. For categorical outcome variables, association
with baseline variables was determined with indepen-




Twenty-two subjects were recruited [50% female,
mean age 50 (standard deviation  11) years] from 19
pedigrees. Twenty subjects had ‘classical’ mutations in
epidermal growth factor-like repeats (EGFr) 1 to 6,
and two in EGFr 7 to 34 [3]. Cohort characteristics
are shown in Table 1. Two subjects declined MRI at
year 2. One patient developed acute leukaemia and
did not complete all investigations at year 2 but did
undergo MRI.
Clinical changes
During the study, a new stroke or TIA occurred in
five subjects (23%). New moderate or severe disability
occurred in one subject (5%). The composite clinical
outcome occurred in five subjects (23%) by study
completion.
There were no significant changes over time in exec-
utive function, attention and working memory or
Trails B minus A time (see Appendix S2, Table S1).
Processing speed differed significantly over time
(Table 1). Post hoc pairwise comparisons showed dif-
ferences were due to an improvement in scores at year
1 compared to baseline (P = 0.003) and a decline
between year 1 and 2 (P = 0.011). There was no over-
all difference between baseline and year 2 (P = 1).
Structural MRI changes
Normalised SH volume increased over the study
(Table 1). There was a mean increase of 0.57% [95%
confidence interval (CI): 0.39 to 0.75, P < 0.001]
between baseline and year 2. There was a significant
decline in brain volume from baseline and year 2, mea-
sured using SIENA, with a PBVC of −0.87% (95% CI:
−0.4 to −1.3, P = 0.001). Numbers of lacunes and
microbleeds significantly increased over the study per-
iod. Three subjects had no lacunes at baseline, and none
of these subjects developed incident lacunes during the
study period, although one subject (aged 30 years) did
not have imaging at year 2. (See Appendix S2, Fig-
ure S1, for spaghetti plots of MRI variables).
Vascular changes
Grey matter CBF changed over the study period
(Table 1). There was a mean decrease from baseline
(49  10 ml/100 g/min) to year 2 (45  9 ml/100 g/
min) of 3.2 ml/100 g/min (95% CI: 0.6 to 5.7,
P = 0.019). Brain CVR, FMD, PWV and blood pres-
sure did not significantly change over the study
(Table 1). CIMT significantly increased over the study
period, with a mean increase of 0.06 mm (95% CI:
0.02 to 0.10, P = 0.01) between baseline and year 2
(see Appendix S2, Figure S2 for spaghetti plots of key
vascular and neuropsychological variables).
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Relationship of vascular measures with clinical and
neuropsychological changes
There was no statistically significant difference in base-
line CBF, CVR, FMD, CIMT or PWV in subjects who
did obtain the composite clinical outcome compared to
those who did not (Appendix S2, Table S2). No factor
significantly correlated with change in processing
speed, executive function, or Trails B minus A time.
Baseline grey matter CBF was lower in subjects who
showed a decline in attention and working memory [de-
cline, 40 (8) ml/100 g/min vs. no decline 52 (6) ml/
100 g/min, P = 0.009; see Appendix S2, Table S3].
Relationship of vascular measures with structural MRI
changes
Lower CBF at baseline was correlated with increased
normalised SH volume change at year 2 (Table 2 and
Fig. 2a). At baseline, grey matter CBF and nor-
malised SH volume were not significantly correlated
(n = 17, rs = −0.417, P = 0.096), but they were at
both 1-year (n = 22, rs = −0.483, P = 0.023) and 2-
year follow-up (n = 19, rs = −0.591, P = 0.008).
Lower PWV at baseline was also correlated with
higher normalised SH volume change by year 2
(Table 2), but PWV did not correlate with normalised
SH volume at individual time-points (data not
shown). Higher age and CIMT at baseline were corre-
lated with an increased rate of brain atrophy
(Table 2).
No baseline vascular marker (FMD, CBF, CVR,
CIMT, PWV) significantly predicted number of inci-
dent lacunes or incident microbleeds (Appendix S2,
Table S4).
Discussion
In this longitudinal study in a cohort of subjects with
CADASIL, baseline CBF was predictive of change in
subcortical hyperintensity volume over a 2-year fol-
low-up period. CBF merits further assessment as both
a potential biomarker of disease progression and a
therapeutic target.
Our study demonstrated a longitudinal decline in
CBF in CADASIL patients. A 6% decline in CBF
over 2 years is higher than that reported in healthy
populations of 0.45% per annum, also using ASL
[26]. ASL offers an evolving, non-invasive and repeat-
able method of perfusion imaging. This high percent-
age change over a short time period suggests this
marker may have utility in short clinical trials,
Table 1 Change over study period in MRI, neuropsychological and vascular measures with repeated measures comparisons
na Baseline Year 1 Year 2 P valueb
Clinical characteristics
Age, years, median [range] 22 53 [26–67] — — —
Female, n (%) 22 11 (50%) — — —
Active smoking, n (%) 22 7 (32%) — — —
Years of education, median [IQR] 22 12 [11–15] — — —
History of TIA or stroke, n (%) 22 11 (50%) 11 (50%) 12 (55%) —
mRS ≥ 3, n (%) 22 3 (14%) 3 (14%) 4 (18%) —
Neuropsychological measures
ToPF estimated IQ, mean (SD) 22 97 (13) — — —
Processing speed, median [IQR], composite z-score 18 −0.2 [−1.6 to 0.5] 0.4 [−1.0 to 0.7] −0.1[−0.9 to 0.5] 0.001
Structural MRI measures
No. of lacunes, median [IQR] 19 5 [2 to 15] 5 [3 to 18] 6 [3 to 24] <0.001
No. of microbleeds, median [IQR] 20 1 [0 to 5] 2 [0 to 7] 3 [0 to 9] <0.001
Normalised subcortical hyperintensity volume, %, mean (SD) 19 8.2 (3.1) 8.5 (3.0) 8.8 (3.1) <0.001
Normalised brain volume, L, mean (SD) 19 1.54 (0.09) 1.53 (0.08) 1.53 (0.06) —
Vascular measures
Grey matter CBF, ml/100 g/min, mean (SD) 15 48 (10) 44 (7) 45 (9) 0.022
Brain CVR, %/CO2, mean (SD) 10 10.5 (9.6) 11.8 (10) 7.5 (6.5) 0.321
CIMT, mm, mean (SD) 18 0.63 (0.1) 0.64 (0.1) 0.68 (0.1) 0.009
FMD, %, mean (SD) 12 4.1 (1.4) 4.4 (2.1) 4.7 (1.6) 0.564
PWV, m/S, mean (SD) 14 7.9 (1.1) 7.7 (1.0) 8.1 (1.0) 0.116
Systolic BP, mmHg, mean (SD) 22 120 (11) 125 (12) 121 (15) 0.128
P values <0.05 are shown in bold typeface. BP, blood pressure; CBF, cerebral blood flow; CIMT, carotid intima-media thickness; CVR, cere-
brovascular reactivity; FMD, flow-mediated dilatation; IQ, intelligence quotient; IQR, interquartile range; MRI, magnetic resonance imaging;
mRS, modified Rankin Scale; PWV, pulse wave velocity; SD, standard deviation; TIA, transient ischaemic attack; ToPF, test of premorbid
functioning. aNumber where data are available at all three time-points. bNormally distributed data expressed as mean (SD) and comparisons
made with repeated measures ANOVA. Non-parametric data are expressed as median [IQR] and comparisons were made with the Friedman test.
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although the small study limits the precision of the
estimates in this study.
We found subjects with lower CBF at baseline had
a greater increase in normalised SH volume over time,
suggesting a causal relationship. However, given
subcortical hyperintensities are often a very early find-
ing in CADASIL, preceding both other radiological
changes and often symptoms [27], this relationship is
unlikely to be a simple linear one.
Subjects with lower CBF at baseline had a decline in
attention and working memory over the study. This
was not seen on other measures of subcortical cognitive
function, such as processing speed, which may reflect
the limited changes in these measures over this time per-
iod. Lower CBF and brain CVR was also seen in those
who obtained the composite clinical outcome (i.e. suf-
fered incident strokes or dementia), but this was not
significant (see Appendices S1 and S2, Table 2), and the
small group numbers hamper interpretation.
Altered CBF in CADASIL is a mechanistically
plausible biomarker, but previous studies of brain per-
fusion have been limited, mainly by the requirement
for radiation or contrast. NOTCH3 extracellular
domain acts as a nidus for deposition of other pro-
teins, and accumulates in pericytes and vascular
smooth muscles cells, leading to vessel damage and
dysfunction [11]. The endothelial dysfunction may
relate to disruption of pericytes in capillaries [28],
resulting in impaired control of CBF [29]. It is postu-
lated that capillary dysfunction leads to a decrease in
oxygen extraction efficiency, which can initially be
compensated for by increasing CBF and potentially
by reducing capillary transit time heterogeneity [30].
Early positron emission tomography studies demon-
strated preserved and even hyperaemic cortical perfu-
sion in patients under the age of 30 years, and it was
suggested that age 30 years was the transition zone
for the decline in CBF [31].
Table 2 Baseline vascular markers predicting change in structural







































Significance (2-tailed) 0.043 0.054
n 18 18
CBF, cerebral blood flow; CIMT, carotid intima-media thickness;
PWV, pulse wave velocity; SH, subcortical hyperintensities. *P
value < 0.05.
Figure 2 Predictors of change in normalised subcortical hyperintensity (nSH) volume. (a) Lower cerebral blood flow at baseline was
associated with a higher increase in nSH volume at 2 years. (b) Lower pulse wave velocity at baseline demonstrated a similar relation-
ship. Line of best fit (solid line) and 95% confidence intervals of the mean (dashed lines) are shown.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
BRAIN IMAGING FACTORS IN CADASIL 225
As damage to vessels accumulates, CBF may
decrease to minimise functional shunting and maintain
flow-metabolism coupling. Attenuated functional
hyperaemia is seen in 6-month CADASIL mouse
models even before arteriolar damage is incurred [12],
suggesting unmasking of capillary dysfunction by
additional demands. Later in the disease, there is
likely a critical point at which the extent of damage
leads to a drop in CBF and acceleration of the disease
process. SPECT studies have shown global hypoperfu-
sion that appeared worse in older and more severely
affected subjects [32], but perfusion results were not
always clearly related to clinical outcomes [33].
The evidence for the relationship between CBF and
hyperintensities remains conflicting. A recent cross-
sectional study using ASL suggested CBF in white
matter hyperintensities was correlated with global cog-
nitive function, and was a better predictor than mean
diffusivity [34]. An immunotherapy study in CADA-
SIL mice, showed that binding of a mouse mono-
clonal antibody to the NOTCH3 extracellular domain
protected against impaired CBF flow responses to
both neural activity and vasodilators, although this
did not influence deposition of granular osmiophilic
material or stop white matter lesion development [35].
High-field MRI combining both ASL and direct visu-
alisation of small vessels in studies including earlier,
pre-symptomatic subjects may allow investigation of
this relationship in more detail. Further validation
against clinical events over time in a larger sample
would be required to strengthen the case for CBF to
be considered a potential surrogate end-point.
Cerebral blood flow and vascular haemodynamics
may also be a target for therapeutics in CADASIL.
Currently, treatment is limited to conventional stroke
preventative treatments and addressing risk factors.
Whilst drugs that temporarily increase or improve
vascular haemodynamics may hypothetically offer
some symptomatic benefit, for example acetazolamide
[36], disease modifying therapeutics are likely to need
to target the drivers of impaired vascular function.
The immunotherapy study in CADASIL mice had
beneficial effects on cerebrovascular function. Our
recent study using biopsy samples from subjects with
CADASIL as well as CADASIL mice models, showed
aberrant responses in the Notch3-Nox5/ER stress/
ROCK signalling pathway leading to impaired vasore-
laxation, blunted vasoconstriction and hypertrophic
remodelling [14]. Administration of inhibitors of
Notch3 function including fasudil resulted in amelio-
ration of impaired vasorelaxation. Therefore, preclini-
cal studies are already focusing on this for therapeutic
targets, and our ability to measure these changes in
human subjects is important.
Changes in structural MRI markers were not the
direct focus of this study but were similar to those
reported in a recent longitudinal cohort study of 160
subjects with CADASIL [37]. In that study, the mean
annualised rate of white matter hyperintensities volume
increase over 3 years was 0.28% of the intracranial cav-
ity, and the annualised rate of brain volume loss was
0.45%, and these variations were statistically significant
from around 18 months. In our study of 22 subjects,
the mean annualised change was 0.29% (for subcortical
hyperintensities) and 0.44%, respectively. Our replica-
tion in a smaller cohort supports the generalisability of
these measures when performed using automated or
semiautomated techniques and supports their use in
multicentre clinical trials. Limited change in clinical
and neuropsychological markers concurs with larger
datasets [10,37] and confirms the challenge of their use
over short follow-up periods. Practice effects on cogni-
tive measures are relevant and likely explain the
improvement in processing speed between baseline and
year 1, and in a small cohort, patient mood and fatigue
may introduce additional variability.
Markers of large-vessel health were also explored in
this study. There was a suggestion that low PWV at
baseline was associated with increase of SH volume
over time. This would be a surprising relationship, and
may reflect the limited range of values for PWV in this
study. High aortic stiffness, represented by higher PWV
measurements, is generally thought to have an adverse
effect on the brain being associated with lower CBF in
non-CADASIL populations [38]. However, these popu-
lations are generally older, with higher rates of hyper-
tension and a wider range of PWV readings. CIMT
results were consistent with previous observations in
both general and CADASIL populations [39,40].
CIMT at baseline (and increasing age) was associated
with brain atrophy in this study. CIMT increased dur-
ing the study period. Increase in CIMT over time may
be seen with aging; however, measurement error for
CIMT can be in the region of 0.03 to 0.05 mm [40], and
thus, correlation with individual changes in imaging or
clinical parameters should be interpreted cautiously.
Given the known interactions of CADASIL with fac-
tors such as smoking and hypertension [7], our findings
may support that large vessel vascular function interac-
tions warrant ongoing study.
The methodological strengths of this study include
the prospective design and the quantitative assessment
of normalised SH volume and brain atrophy, which
demonstrated high concurrence with other studies. All
MRI scans were performed on the same scanner, and
all neuropsychological tests by the same assessor.
The major limitation of this study is the small num-
ber of subjects. This reflects the ongoing apparent
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clinical rarity of CADASIL, despite evidence of signif-
icant underdiagnosis. All subjects underwent extre-
mely detailed assessment. Small numbers mean we
have to be cautious in drawing definitive conclusions,
but the aim of this study was to explore potential
measures that may warrant further research. There
were insufficient subjects to explore the effect of typi-
cal and atypical mutations, which may have pheno-
typic relevance [3]. Issues with reliability of gas
delivery methods and monitoring need to be consid-
ered going forward, as not all subjects could have
accurate CO2 levels measured [41]. A ceiling effect for
normalised SH volume was not accounted for in this
study but may be relevant in other cohorts. Not all
associations found in our baseline study could be
explored further at year 2 follow-up.
In conclusion, we found CBF to predict progression
of subcortical hyperintensity volume over a 2-year per-
iod, observed longitudinal changes in CBF many times
larger than changes seen in non-CADASIL subjects
and, in addition, confirmed progression of several
structural indices in CADASIL over a 2-year period.
CBF may offer a therapeutic target and biomarker of
relevance and should be explored in larger trials.
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